J 2016

Elevation of cardiac troponin T in patients with amyotrophic lateral sclerosis

MACH, Lukáš, Tomas KONECNY, Kateřina HELÁNOVÁ, Allan S. JAFFE, Eric J. SORENSON et. al.

Basic information

Original name

Elevation of cardiac troponin T in patients with amyotrophic lateral sclerosis

Authors

MACH, Lukáš (203 Czech Republic, belonging to the institution), Tomas KONECNY (203 Czech Republic), Kateřina HELÁNOVÁ (203 Czech Republic, guarantor), Allan S. JAFFE (840 United States of America), Eric J. SORENSON (840 United States of America), Virend K. SOMERS (840 United States of America) and Guy S. REEDER (840 United States of America)

Edition

Acta Neurologica Belgica, Heidelberg, Springer Heidelberg, 2016, 0300-9009

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.722

RIV identification code

RIV/00216224:14110/16:00089280

Organization unit

Faculty of Medicine

UT WoS

000387681300019

Keywords in English

Acute coronary syndrome; Neuromuscular disease; Amyotrophic lateral sclerosis; Troponin T

Tags

Tags

International impact, Reviewed
Změněno: 12/5/2017 12:32, Mgr. Michal Petr

Abstract

V originále

Limited evidence suggests that specificity of cardiac troponin T (cTnT), a highly sensitive biomarker of myocardial injury, is reduced in patients with skeletal myopathies. Whether amyotrophic lateral sclerosis (ALS) the most common motor neuron disease could be also associated with abnormal plasma or serum cTnT levels remains unclear. Our objective was to assess cTnT levels in patients with ALS without known cTnT elevating conditions. Among ALS patients seen at our institution until 2012 we identified those who had their cTnT measured. Patients who suffered from conditions known to elevate cTnT were excluded. A case–control analysis comparing cTnT levels of these ALS patients to matched non-ALS controls fulfilling the same inclusion criteria was performed. We included 40 ALS patients of whom 27 (68 %) patients had a positive cTnT. In the control group (n = 40), 2 (5 %) tested as cTnT positive. Among the ALS patients who underwent cTnT evaluation on more occasions (n = 7; median followup = 1.08 years), 2 (29 %) patients tested positive during the initial measurement while 6 (86 %) of them had positive cTnT at the subsequent evaluations. ALS patients with increased cTnT had been diagnosed with ALS significantly earlier than those without the elevation. Our findings raise the possibility that ALS may cause cTnT elevations. Further studies are needed to confirm these findings, clarify the pathophysiological mechanism, and establish the significance of cTnT elevations in patients with ALS.